Current status of gene therapy for breast cancer: progress and challenges.

about

Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.

P2860

Q36024654-F30EF1D0-6B78-4363-8518-F77778015AB3 Q47110708-D64EFABE-6BA9-440C-90DC-4ADE3305DBF4

P2860

Current status of gene therapy for breast cancer: progress and challenges.

Item

http://www.wikidata.org/entity/Q38270806

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Current status of gene therapy for breast cancer: progress and challenges.

@en

type

Item

label

Current status of gene therapy for breast cancer: progress and challenges.

@en

prefLabel

Current status of gene therapy for breast cancer: progress and challenges.

@en

P1476

Current status of gene therapy for breast cancer: progress and challenges.

@en

P2093

Cian M McCrudden

http://www.w3.org/2001/XMLSchema#string

Helen O McCarthy

http://www.w3.org/2001/XMLSchema#string

P2860

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

Transcriptional Targeting in Cancer Gene Therapy

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines.

Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells.

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells.

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.

P304

209-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TACG.S54992

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25419154

http://www.w3.org/2001/XMLSchema#string

P921

gene therapy

P932

4234158

http://www.w3.org/2001/XMLSchema#string

Current status of gene therapy for breast cancer: progress and challenges.

about

P2860

P2860

Current status of gene therapy for breast cancer: progress and challenges.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932